Education
About Us
Working with TipRanks
Follow Us
AbCellera Biologics (ABCL)
NASDAQ:ABCL
Earnings Data
Report Date
Feb 24, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.15Last Year’s EPS
-0.12Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call highlights AbCellera's successful transition to a clinical-stage biotech and strong liquidity position, but also notes increased net loss and R&D expenses. While revenue has increased, the stagnation in partner-initiated programs presents a challenge.Company Guidance
Transition to Clinical-Stage Biotech
AbCellera completed its transition from a platform company to a clinical-stage biotech with the initiation of Phase I clinical trials for ABCL635 and ABCL575, both of which are progressing as planned.
Strong Liquidity Position
AbCellera ended the quarter with approximately $680 million in available liquidity, including $520 million in cash and cash equivalents and $160 million in available committed government funding.
New Clinical Manufacturing Facility
Activities have started at AbCellera's new clinical manufacturing facility, and platform investments are substantially complete.
Appointment of New Chief Medical Officer
Dr. Sarah Noonberg, a physician-scientist with over 20 years of clinical drug development experience, was appointed as the new Chief Medical Officer.
Increase in Revenue
Revenue for the quarter was $9 million, up from $7 million in the same quarter of last year, predominantly from research fees relating to work on partnered programs.
ABCL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ABCL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 06, 2025 | $4.53 | $3.91 | -13.69% |
Aug 07, 2025 | $4.24 | $4.25 | +0.24% |
May 08, 2025 | $2.01 | $2.03 | +1.00% |
Feb 27, 2025 | $2.92 | $2.58 | -11.64% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does AbCellera Biologics (ABCL) report earnings?
AbCellera Biologics (ABCL) is schdueled to report earning on Feb 24, 2026, After Close (Confirmed).
What is AbCellera Biologics (ABCL) earnings time?
AbCellera Biologics (ABCL) earnings time is at Feb 24, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ABCL EPS forecast?
ABCL EPS forecast for the fiscal quarter 2025 (Q4) is -0.15.